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Aims: The Canals of Hering (CoH), which are the most peripherally located bile 
drainage pathway, are considered a niche of hepatic progenitor cells. Recently, CoH loss 
has been described as an early feature of primary biliary cirrhosis (PBC). We 
investigated the correlation between CoH loss and the histopathological variables of 
PBC. 
Methods: Liver biopsy specimens from 62 PBC patients (M:F = 8:54, age = 58 ± 12 
years) were evaluated prior to ursodeoxycholic acid treatment. Liver biopsies of patients 
with normal liver (n = 11), chronic viral hepatitis (n = 36), and non-alcoholic fatty liver 
disease (n = 13) were used as controls. The number of CoH per definite area of hepatic 
parenchyma (c/p ratio) was calculated in individual cases. We compared the c/p ratios of 
PBC patients with that of controls and analysed the correlations with histological 
variables and clinical features. 
Results: The c/p ratios in PBC patients with mild and extensive fibrosis were lower than 
those in controls with each degree of fibrosis. The c/p ratios were negatively correlated 
with stage, fibrosis, bile duct loss, orcein-positive granule deposition and hepatitis 
activities in PBC (p < 0.01) and with alkaline phosphatase and total bilirubin levels at 
liver biopsies (p < 0.05).  
4 
 
Conclusions: The number of CoH was low in early stages and further decreased with 
stage progression in PBC. CoH loss, reflecting a reduced supply of progenitor cells to the 







Primary biliary cirrhosis (PBC) is an autoimmune liver disease that is characterised by an 
immune-mediated destruction of intrahepatic bile ducts. Histologically, interlobular bile 
ducts are selectively affected, and this presents as chronic non-suppurative destructive 
cholangitis (CNSDC). The progressive loss of these small bile ducts is followed by 
prolonged cholestasis and cirrhosis(1-4). Enhanced apoptosis has been suggested as the 
major mechanism of bile duct loss in PBC(5). The balance of cell proliferation and loss 
is important in the maintenance of tissue homeostasis, including that of the biliary 
system(6), but the mechanisms that compensate for the enhanced loss of biliary epithelial 
cells in PBC have not been adequately clarified. 
   Canals of Hering (CoH), which are the most peripherally located bile drainage 
pathway connecting bile ducts and bile canaliculi, are considered to be a niche of hepatic 
progenitor cells (HPCs)(7, 8), and play important roles in liver and biliary regeneration 
in hepatobiliary diseases(9-16). CoH are visualised using immunohistochemistry for 
biliary markers, such as cytokeratin (CK) 7 and CK19. In various chronic liver diseases, 
such as chronic viral hepatitis and non-alcoholic steatohepatitis, a correlation between 
HPC activation and fibrotic and necroinflammatory activity has been reported(9, 13, 17, 
18). While the CoH loss has been reported as a feature of PBC, particularly in its early 
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stages(19, 20), the relationships between the CoH loss and other histological findings of 
PBC, such as bile duct loss and fibrosis, are unclear. 
   Here we investigated the correlation between CoH loss and other histological 
variables, particularly those that are related to the staging and activity of PBC and the 




Materials and Methods 
Patient selection and tissue preparations  
A total of 62 PBC patients who were clinicopathologically diagnosed based on liver 
biopsies (59 needle and 3 wedge liver biopsies) were enrolled in this study. These 
patients were selected from the hepatobiliary disease files of Kanazawa University 
Hospital. They were divided into 2 groups: i) patients with adverse outcome  [n = 16, 
cases showed cirrhosis-related conditions at biopsy (n = 6) or during 7.6 ± 5.8 yrears 
follow up (n = 10); histologically proven cirrhosis or cirrhosis-related complications 
and/or symptoms, such as ascites, ruptured and/or endoscopically treated 
gastroesophageal varices, hepatic encephalopathy, hyperbilirubinemia (≥2.0 mg/dL) or 
hepatocellular carcinoma]; and ii) patients without adverse outcome (n = 46, without 
these conditions during the 6.7 ± 6.2 years of follow-up). Biochemical data [levels of 
alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γ-GTP), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin] were 
collected for 6 months before the first biopsies (n = 62) and after 1 year of therapy in 34 
of the 62 patients who were treated with ursodeoxycholic acid (UDCA) only for 1 year 
or more. We examined 62 liver biopsies that were taken prior to UDCA therapy and 8 
additional needle liver biopsies that were taken at the follow-up biopsies.  
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   Needle liver biopsy specimens of patients with normal livers (n = 11), chronic viral 
hepatitis types C (n = 20) and B (n = 16) and non-alcoholic fatty liver disease (NAFLD, 
n = 13) were used as controls. All liver biopsy specimens were routinely processed; thin 
consecutive sections were stained with haematoxylin and eosin, reticulin, Azan–Mallory 
and Sirius Red stains and CK19 immunohistochemistry. Furthermore, orcein staining 
was performed in PBC cases.  
CK19 immunohistochemistry 
The slides were deparaffinised, and antigen retrieval was performed by microwaving in 
10 mM citrate buffer (pH 6) for 20 min. After blocking of endogenous peroxidase and 
incubation in normal goat serum (1:10; Vector Laboratories, Inc., Burlingame, CA, 
USA) for 20 min, the deparaffinised sections were incubated overnight at 4 °C with a 
monoclonal mouse antibody against CK19 (clone RCK108; 1:100; DakoCytomation; 
Dako Japan, Tokyo, Japan). The sections were then incubated at room temperature for 1 
h with goat anti-mouse immunoglobulins that were conjugated to peroxidase-labelled 
dextran polymer (EnVision; DakoCytomation). The reaction products were developed by 
immersing the sections in a 3,3’-diaminobenzidine tetrahydrochloride (DAB) solution 




Immunohistochemical and histological evaluation 
Using CK19 immunohistochemistry, CoH were defined according to Saxena et al(19). In 
brief, single to small clusters of less than 5 CK19-positive cells within hepatic lobules 
were counted. CK19-positive cells on limiting plates were not counted to eliminate 
ductular reactions (shown in Fig. 1). Furthermore, the ratios of the total number of CoH 
per definite area of hepatic parenchyma of each liver biopsy specimen were calculated to 
evaluate the relative number of CoH in individual cases according to the procedure 
summarised in Fig. 2. Namely, the hepatic parenchyma area was measured as follows. 
The sections were stained with Sirius Red and photographed at 20× magnification under 
an Olympus light microscope. Furthermore, the digital images were created and 
reproduced on a computer using the image processing software cellSens Standard 
(Olympus Corporation, Tokyo, Japan). Image analysis was performed with a resolution 
of 400 pixels/inch using Photoshop software (version 7.0.1; Adobe Systems Inc.) to 
quantify the parenchymal area of the specimens, which were expressed as pixels.  
   PBC liver biopsy specimens were routinely examined and evaluated with reference to 
the new grading and staging systems proposed by us(21, 22), which are summarised in 
Table 1. In controls, liver biopsies were routinely examined, and liver biopsies of patients 
with chronic viral hepatitis and NAFLD were evaluated with reference to the staging 
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according to Metavir and Brunt(23, 24), respectively; liver biopsies of the former were 
from F 0, 1, 2, 3 and 4, and those of the latter from stage 0, 1, 2, 3 and 4. 
Statistical analyses 
Continuous variables are expressed as mean ± standard deviation (SD). Non-normally 
distributed variables were expressed as medians and interquartile ranges (IQR). The 
correlations and comparisons of the c/p ratio with each histological and clinical finding 
were examined using Spearman’s correlation coefficients by rank tests and Wilcoxon 
signed-rank tests, respectively. All analyses were 2-sided and a p value of <0.05 was 
considered significant. All statistical analyses were performed using JMP software 8.0 




A summary of the clinical and histological findings of the 62 patients with PBC at the 
time of diagnosis are shown in Table 2. The immunohistochemistry for CK19 of CoH is 
shown in Figure 1. In normal livers, several CK19-positive CoH were scattered around 
portal tracts, whereas CoH were few or absent in patients with PBC (Fig. 1).  
 
Relationship between histological grade and stage and CoH in PBC 
The c/p ratios of PBC stages 1, 2, 3 and 4 (n = 11, 35, 9 and 7, respectively) were 6.9 ± 
4.6, 5.7 ± 4.7, 3.2 ± 3.4 and 0.23 ± 0.60 (× 10−6 each), respectively. In addition, the c/p 
ratio was negatively correlated with hepatitis activity (ρ = −0.339; p < 0.01), stage (ρ = 
−0.475; p < 0.01) and fibrosis, bile duct loss and orcein-positive granule deposition 
scores (ρ = −0.385, −0.529 and −0.559, respectively; p < 0.01; Fig. 3A–F). The c/p ratio 
was not associated with cholangitis activities (ρ = −0.052; p = 0.69). 
   In 8 (cases A–H) of the 62 patients, follow-up biopsies were obtained after 8 ± 5 
years of therapy, including UDCA. The CoH and histological grades, scores and stage of 
the liver biopsies are summarised in Table 3. Although the cohort was too small for 
statistical analysis, CoH decreased in 3 cases (cases A–C) whose follow-up biopsies 
showed bile duct loss and orcein-positive granule deposition that was advanced more 
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than 2 scores. In contrast, neither CoH loss nor histological progression were observed in 
2 cases (cases D and E). In case F, there was already no CoH in the specimen at 
diagnosis. Two cases (cases G and H) showed increasing CoH, despite stage progression. 
As for case G, an association with NAFLD was observed at the follow-up biopsy. In case 
H, there was discrepancy between bile duct loss/orcein-positive granule deposition and 
fibrosis progression, which may indicate the presence of superimposed autoimmune 
hepatitis features in this case(3).  
 
CoH and clinical features of PBC  
The c/p ratio was not associated with age (Fig. 4A), sex (Fig. 4B) or symptomatic or 
asymptomatic presentation (data not shown). As for laboratory data, the c/p ratio was 
negatively correlated with ALP, total bilirubin and IgG levels at the time of the biopsies 
(ρ = −0.310, −0.256 and −0.285, respectively; p < 0.05; Fig. 4C–E). Anti-mitochondrial 
antibody and antinuclear antibody positivity and the levels of γGTP, AST, ALT, serum 
albumin and IgM showed no clear significant correlation (data not shown).  
   Among 34 patients (stage 1/2/3/4 = 5/18/8/3 cases) who were treated with UDCA for 
more than 1 year, the ones with increased levels of total bilirubin in response to UDCA 
13 
 
(poor responders, 4 cases) showed no CoH in the specimens and significantly lower c/p 
ratios compared with responders (30 cases) (p < 0.01) (Fig. 4F).  
   The c/p ratios of PBC patients showed histologically proven cirrhosis or 
cirrhosis-related complications and/or symptoms (i.e. ascites, hyperbilirubinemia, 
ruptured and/or endoscopically-treated gastroesophageal varices, hepatic encephalopathy 
or hepatocellular carcinoma) at the biopsies or during the 7.6 ± 5.8 years after follow-up 
(n = 16) were also significantly lower compared with those of the patients without these 
conditions for 6.7 ± 6.2 years (n = 46; p < 0.05) (Fig. 4G).  
 
CoH in PBC and control livers 
Furthermore, the c/p ratios of PBC patients were compared with those of the controls 
obtained from patients with normal livers [n = 18, c/p ratio = 15 ± 13 (× 10−6)], chronic 
viral hepatitis of F0–1 [n = 12, c/p ratio = 18 ± 11 (× 10−6)] and F2–4 [n = 24, c/p ratio = 
34 ± 33 (× 10−6)], NAFLD of stage 0–2 [n = 7, c/p ratio = 26 ± 16 (× 10−6)] and stage 
3–4 [n = 6, c/p ratio = 82 ± 45 (× 10−6)] (Fig. 5). The c/p ratios of the controls were 
significantly higher compared with those of the PBC cases with a fibrosis score of 0–1 [n 
= 45, c/p ratio = 6.0 ± 4.6 (× 10−6)] and 2–3 [n = 17, c/p ratio = 1.9 ± 2.9 (× 10−6)]. In 
addition, the c/p ratios were positively correlated with the fibrosis stage of patients with 
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NAFLD (ρ = 0.641; p < 0.05), and NAFLD stage 3–4 cases showed increased c/p ratios 
compared with those of the normal livers (p < 0.05). Regarding chronic viral hepatitis, 





The data obtained here are summarised as follows: i) the number of CoH was 
decreased in patients with PBC not only in the early stages but also in advanced stages in 
comparison with controls of comparable stages; ii) the decrease in CoH correlates with 
the histological stage and findings related to PBC staging; iii) CoH decreased in 
follow-up biopsies, showing stage progression with bile duct loss and a greater than 
2-score increase in orcein-positive granule deposition; iv) CoH loss was also associated 
with liver dysfunction and v) the responders to therapy showed higher c/p ratios than the 
non-responders, and the cases with cirrhotic conditions showed lower c/p ratios than 
those without cirrhotic conditions. Although this study using liver biopsies has some 
limitations regarding the evaluation of clinicopathological features with respect to 
disease progression or severity given the patchy distribution of histological changes in 
PBC, the results listed above, particularly ii) and iii), suggest that CoH loss parallels 
disease progression in PBC. Moreover, an observation of CoH loss in the early stage may 
reflect advanced bile duct damage and associated conditions in PBC.  
 Several studies have suggested that CoH loss is observed in early stages and that 
such a loss may be a feature of the earliest changes in PBC(19, 20). In the present study, 
we confirmed these findings and additionally demonstrated an association between CoH 
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loss and disease progression, particularly bile duct loss and cholestasis. Furthermore, not 
only the histological variables but also the clinical findings, such as biochemical data and 
patient outcomes (Fig. 4), were associated with the c/p ratios in this study. This study 
observed that the c/p ratio was higher in biochemical responders to UDCA and in 
patients with non-cirrhotic conditions than in non-responders to UDCA and those with 
cirrhotic conditions, respectively, in PBC. These data suggested that the degree of CoH 
loss differed among patients and that patients with lesser reduction of CoH may respond 
well to UDCA and belong to a less advanced stage. This suggests that in addition to 
staging, higher c/p ratios may reflect favourable conditions and prognoses. A prospective 
study appears mandatory to verify this hypothesis. Moreover, 2 of 8 patients in this study 
with follow-up biopsies showed no progression of PBC. The c/p ratios appeared to 
increase in these histological responders to UDCA; however, this number of cases is too 
small to allow any speculation. Further studies with a larger cohort will be needed to 
investigate whether UDCA is able to reverse CoH loss. 
  Saxena et al.(25) reported an increase in the numbers of CoH in cases involving 
Scheuer’s stage II and III in comparison with histological stage 0, which is defined as a 
normal portal tract containing a normal bile duct. The disparity between our findings and 
those reported by Saxena et al. may be due to the different staging system. Scheuer’s 
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staging system is defined by a mixture of ductopathy and fibrosis(26). The difference in 
the definition of the c/p ratios may also be responsible for this disparity; the c/p ratio in 
our study, which was the ratio of the number of CoH in a definite area of parenchyma, is 
used to evaluate biopsies with or without extensive fibrosis and lobular disarray precisely, 
and that used in Saxena’s data was the ratio of CoH/portal tracts. To confirm this 
prospect, we counted the c/p ratio in accordance with Scheuer’s staging system, and the 
c/p ratio was shown to decrease gradually along with stage as in the new staging system 
(data not shown). Therefore, the difference in staging and definition with respect to 
counting CoH did not affect the gradual loss of CoH observed in this study along with 
the histological stage. 
   Kahn et al.(20) suggested that there are two hypothetic mechanisms of CoH loss in 
the minimal change of PBC: i) their being destroyed by an immune attack(19) or ii) 
their disappearing as a result of differentiation into hepatocytes(8, 15). In PBC livers at 
early stages, focal necrosis occasionally occurs with lymphocytic infiltration and 
Kupffer cell hyperplasia in the hepatic parenchyma, suggesting that these lesions may 
reflect progenitor loss by immunological cells, as observed in the chronic 
non-suppurative destructive cholangitis characterizing PBC. The findings that the c/p 
ratios correlated with hepatitis activities in this study (Fig. 3F) support the idea of an 
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immunopathological attack on HPCs, although there was no correlation between 
cholangitis activities and c/p ratios (Fig. 3E). While the reason(s) for progressive CoH 
loss remains speculative, the loss or absence of such progenitor cells in the liver may be 
followed by an insufficient supply of biliary committed cells to the bile ductules and 
interlobular bile ducts. This may be followed by the impaired replacement of biliary 
epithelia in the damaged interlobular bile ducts and by the irreversible loss of 
interlobular bile ducts as well in PBC. More studies are needed to answer the question 
of what causes the CoH decrease in PBC.    
 In comparison with other control liver diseases, PBC cases showed significantly 
lower c/p ratios than other diseases in each degree of fibrosis (Fig. 5), which 
corresponded to the findings of previous studies(19, 20, 25). It has been reported that the 
activation of HPCs is associated with fibrosis progression(27) in chronic viral hepatitis(9, 
12, 18, 28) and NAFLD(10, 13, 29). Namely, liver injury due to viral infection or 
oxidative stress causes hepatic stellate cell activation as well as also HPC expansion for 
liver regeneration. HPC expansion, including ductular reaction, has been thought to drive 
fibrosis through the production of agents such as connective tissue growth factor and/or 
epithelial–mesenchymal transition, which contributes to the portal myofibroblast pool. 
Our results were partially compatible with these findings. Specifically, NAFLD cases 
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showed statistical correlations between the c/p ratios and the degree of fibrosis. However, 
in cases with chronic viral hepatitis, such a relationship was unclear. This may be 
because of the large variation in the c/p ratios and the small number of cases with each 
degree of fibrosis. At least, unlike in PBC, there was no tendency for CoH loss according 
to stage progression in chronic viral hepatitis and NAFLD. Moreover, an evaluation of 
the follow-up biopsies of PBC patients showed that the c/p ratio of a case with 
accompanied NAFLD was preserved, while the score of bile duct loss progressed in the 
follow-up biopsy compared with that in the biopsy performed at diagnosis (Table 3, case 
G). These facts suggested that the fibrogenesis in PBC may not be mediated by HPCs 
within CoH. The prolonged cholestasis and the destruction of limiting plates associated 
with progressive fibrosis of PBC may be responsible for activation of hepatic stellate 
cells followed by fibrosis(30, 31). 
   In conclusion, CoH loss was observed in PBC livers in the early stages, and it was 
worse in advanced stages. PBC patients who were responders to therapy and the ones 
with non-cirrhotic conditions showed relatively higher c/p ratios. Further studies on 






Table 1-1. Grading of the necroinflammatory activity of primary biliary cirrhosis 
A. Cholangitis activity (CA) 
Grade                    Criteria 
0 (no activity)          No cholangitis but mild damage to the epithelium of the duct may be present 
1 (mild activity)        One evident chronic cholangitis in the specimen 
2 (moderate activity)    More than two bile ducts with evident chronic cholangitis 
3 (marked activity)      At least one CNSDC in the specimen 
Abbreviation: CNSDC, chronic non-suppurative destructive cholangitis 
 
B. Hepatitis activity (HA) 
Grade                   Criteria 
0 (no activity)           No interface hepatitis and no or minimum lobular hepatitis 
1 (mild activity)         Interface hepatitis affecting 10 continuous hepatocytes at a limiting plate in 
one portal tract or fibrous septa and mild-to-moderate lobular hepatitis 
2 (moderate activity)    Interface hepatitis affecting 10 continuous hepatocytes at a limiting plates in 
more than two portal tracts or fibrous septa and mild-to-moderate lobular 
hepatitis 
3 (marked activity)     Interface hepatitis affecting 20 continuous hepatocytes at limiting plate in more 
than half of theportal tracts and modetatelobular hepatitis or bridging/zonal  
necrosis 
 
Table 1-2. Scoring for the staging of primary biliary cirrhosis 
A. Fibrosis 
Score             Criterion 
0          No portal fibrosis or fibrosis limited to portal tracts 
1          Portal fibrosis with periportal fibrosis or incomplete septal fibrosis 
2          Bridging fibrosis with variable lobular disarray 
3          Liver cirrhosis with regenerative nodules and extensive fibrosis 
 
B. Bile duct loss 
Score             Criterion 
0          No bile duct loss 
1          Bile duct loss in <1/3 of portal tracts 
2          Bile duct loss in 1/3–2/3 of portal tracts 




C. Orcein-positive granules deposition (orcein) 
Score            Criterion 
0          No deposition of granules 
1          Deposition of granules in a couple of zone 1 hepatocytes at <1/3 of portal tracts 
2          Deposition of granules in a variable number of zone 1 hepatocytes at 1/3–2/3 of portal 
tracts 












Table 2. Main clinical, laboratory and pathological characteristics of the 62 patients with primary biliary 
cirrhosis 
 
Age (mean ± SD years)                        57 ± 11 
Sex (males:females)                            8:54 
AMA or M2Ab (+:−)                          43:19 (positivity 69%) 
ANA (+:−)                                  39:23 (positivity 63%) 
Symptomatic:asymptomatic                     22:40 
Laboratory data at the time of biopsy              median (IQR)  
 ALP (normal range: 115–359) (IU/L)              482 (750–295) 
γ-GTP (normal range: 10–47) (IU/L)              130 (272–79) 
 AST (normal range: 13–33) (IU/L)                42 (55–28) 
 ALT (normal range: 6–27) (IU/L)                 40 (55–27) 
 Total bilirubin (normal range: 0.3–1.2) (mg/dL)      0.7 (0.9–0.5) 
 Albumin (normal range: 4.0–5.0) (g/dL)            4.0 (4.4–3.7) 
Prothrombin time (normal range: 10.6–13.0) (s)      11.3 (11.9–10.9) 
IgG (normal range: 870–1,700) (mg/dL)            1,917 (2,238–1,525) 
IgM (normal range: 46–260) (mg/dL)              302 (446–174) 
Histological characteristicsa) 
 Grade 
 CA 0/1/2/3 (cases)                        10/16/10/26 
   HA 0/1/2/3 (cases)                        12/29/17/4 
Stage 1/2/3/4 (cases)                         11/35/9/7 
 Scores 
 Fibrosis 0/1/2/3 (cases)                      14/31/14/3 
 Bile duct loss 0/1/2/3 (cases)                  26/28/5/3 
 Orcein 0/1/2/3 (cases)                       37/13/3/9 
 
Abbreviations: SD, standard deviation; AMA, anti-mitochondrial antibodies; M2Ab, M2 antibodies; ANA, 
anti-nuclear antibodies; IQR, interquartile range, ALP, alkaline phosphatase; γ-GTP, gamma-glutamyl 
transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IgG, Immunoglobulin G; 
IgM, Immunoglobulin M; a) histological findings related to the new grading and staging system, CA, 
cholangitic activities; HA, hepatitic activities; orcein, orcein-positive granules deposition. 
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Table 3. Comparison of findings at the time of diagnosis and in follow-up biopsies 











area (pixels) c/p ratio 
a) 
A 
1st 2 2 1 0 0 2 6 1,734,440 3.5 
2nd 3 2 2 3 3 4 1 1,063,931 0.94 
B 
1st 1 0 1 0 0 2 5 450,394 11.1 
2nd 0 1 1 3 3 4 3 591,106 5.1 
C 
1st 3 1 1 1 0 2 11 1,433,944 7.7 
2nd 0 2 2 3 3 4 5 813,556 6.1 
D 
1st 3 0 1 0 0 2 2 424,735 4.7 
2nd 3 0 0 1 0 2 4 627,909 6.4 
E 
1st 0 1 1 1 1 2 0 306,375 0 
2nd 0 0 1 1 1 2 2 347,983 5.7 
F 
1st 2 2 2 1 3 3 0 572,812 0 
2nd 0 2 3 3 3 4 0 343,570 0 
G 
1st 3 1 1 0 0 2 3 712,440 4.2 
2nd 2 1 2 2 1 3 9 618,688 14.5 
H 
1st 3 2 1 0 0 2 2 266,990 7.5 
2nd 3 3 3 1 1 3 28 889,556 31.5 
 
Abbreviations: CA, cholangitic activities; HA, hepatitic activities; BDL, bile duct loss; Orcein score, 









Fig. 1 Representative pictures of cytokeratin (CK)19 immunohistochemistry of portal 
tracts. (A) A normal liver, (B) a patient with primary biliary cirrhosis (PBC) of 
CA3, HA1, stage 2 (scores of fibrosis 1, bile duct loss 1, orcein 1) and (C) a 
patient with PBC of CA3, HA1, stage 4 (scores of fibrosis 2, bile duct loss 3, 
orcein 3). The arrows denote the Canals of Hering (CoH; 100× magnification). 
To distinguish these from bile ductules, CK19 positive cells on the limiting 
plates (arrowheads) and clusters of more than 5 cells were eliminated in this 
study. Abbreviations: CA, cholangitic activity; HA, hepatitic activity. 
Fig. 2 (A) Diagram of the procedure used to calculate the c/p ratio. (B) A representative 
digital image of a specimen stained with Sirius Red. The hepatic parenchymal 
area (yellowish zone) was quantified using pixels. All image analyses were 
performed at a resolution of 400 pixels/inch. 
Fig. 3 The c/p ratio of each grade, score and stage in PBC livers. (A) CA, (B) HA, (C) 
stage, (D) fibrosis score, (E) bile duct loss score and (F) orcein score. 
Abbreviations: c/p ratio, the ratio of the number of CoH to the parenchymal 
area; CA, cholangitic activity; HA, hepatitic activity; ρ, correlation coefficient; 
n.s., not significant. 
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Fig. 4 The c/p ratio and clinical features of PBC. (A) Sex, (B) age, (C) serum level of 
ALP, (D) total bilirubin, (E) IgG at biopsy, (F) total bilirubin response to 1 year 
UDCA therapy and (G) those with or without adverse outcomes (an adverse 
outcome being defined by histologically proven cirrhosis or cirrhosis-related 
complications and/or symptoms). As for the laboratory data and UDCA 
responses, this figure includes only the variables that reached statistical 
significance. Abbreviations: c/p ratio, the ratio of the number of CoH to the 
parenchymal area; ρ, correlation coefficient; n.s., not significant; ALP, alkaline 
phosphatase; UDCA, ursodeoxycholic acid.  
Fig. 5 The c/p ratios of patients with PBC and control livers. The c/p ratios of the PBC 
livers with (A) none to mild and (B) severe fibrosis were significantly lower 
compared with those of controls. Abbreviations: c/p ratio, the ratio of the 
number of CoH to the parenchymal area; fibrosis, fibrosis score according to 






Take home messages 
In PBC, the number of canals of Hering (CoH) is low in early stages and further 
decrease with stage progression.  
      CoH loss parallels the histological findings related to the staging of PBC, 
particularly bile duct loss and chronic cholestasis, and also associates with liver 
dysfunction. 
CoH loss, reflecting a reduced supply of progenitor cells to the biliary tree, may 
be involved in the histologic progression of PBC. 
-27- 
References 
1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. The New England 
journal of medicine. 2005 Sep 22;353(12):1261-73. PubMed PMID: 16177252. Epub 
2005/09/24. eng. 
2. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. 
Lancet. 2011 May 7;377(9777):1600-9. PubMed PMID: 21529926. Epub 2011/05/03. 
eng. 
3. Poupon R. Primary biliary cirrhosis: A 2010 update. Journal of hepatology. 
2010;52:745–58. 
4. Nakanuma Y, Ohta G. Histometric and serial section observations of the 
intrahepatic bile ducts in primary biliary cirrhosis. Gastroenterology. 1979 
Jun;76(6):1326-32. PubMed PMID: 437429. Epub 1979/06/01. eng. 
5. Harada K, Ozaki S, Gershwin ME, Nakanuma Y. Enhanced apoptosis relates 
to bile duct loss in primary biliary cirrhosis. Hepatology. 1997 Dec;26(6):1399-405. 
PubMed PMID: 9397977. Epub 1997/12/16. eng. 
6. Harada K, Iwata M, Kono N, Koda W, Shimonishi T, Nakanuma Y. 
Distribution of apoptotic cells and expression of apoptosis-related proteins along the 
intrahepatic biliary tree in normal and non-biliary diseased liver. Histopathology. 2000 
Oct;37(4):347-54. PubMed PMID: 11012742. Epub 2000/09/30. eng. 
7. Theise ND, Saxena R, Portmann BC, Thung SN, Yee H, Chiriboga L, et al. 
The canals of Hering and hepatic stem cells in humans. Hepatology. 1999 
Dec;30(6):1425-33. PubMed PMID: 10573521. Epub 1999/11/26. eng. 
8. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, Theise 
ND. The hepatic stem cell niche: identification by label-retaining cell assay. Hepatology. 
2008 Jun;47(6):1994-2002. PubMed PMID: 18454509. Pubmed Central PMCID: 
2847183. 
9. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson 
JR. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired 
replication, progenitor cells and steatosis. Hepatology. 2005 Apr;41(4):809-18. PubMed 
PMID: 15793848. 
10. Nobili V, Carpino G, Alisi A, Franchitto A, Alpini G, De Vito R, et al. Hepatic 
progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic 
fatty liver disease. Hepatology. 2012 Dec;56(6):2142-53. PubMed PMID: 22467277. 
11. Espanol-Suner R, Carpentier R, Van Hul N, Legry V, Achouri Y, Cordi S, et al. 
Liver progenitor cells yield functional hepatocytes in response to chronic liver injury in 
mice. Gastroenterology. 2012 Dec;143(6):1564-75 e7. PubMed PMID: 22922013. 
-28- 
12. Eleazar JA, Memeo L, Jhang JS, Mansukhani MM, Chin S, Park SM, et al. 
Progenitor cell expansion: an important source of hepatocyte regeneration in chronic 
hepatitis. Journal of hepatology. 2004 Dec;41(6):983-91. PubMed PMID: 15582132. 
13. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, 
Bhathal PS, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with 
altered regeneration and a ductular reaction. Gastroenterology. 2007 Jul;133(1):80-90. 
PubMed PMID: 17631134. 
14. Falkowski O, An HJ, Ianus IA, Chiriboga L, Yee H, West AB, et al. 
Regeneration of hepatocyte ‘buds’ in cirrhosis from intrabiliary stem cells. Journal of 
hepatology. 2003;39(3):357-64. 
15. Zhang L, Theise N, Chua M, Reid LM. The stem cell niche of human livers: 
symmetry between development and regeneration. Hepatology. 2008 
Nov;48(5):1598-607. PubMed PMID: 18972441. 
16. Itoh T, Miyajima A. Liver regeneration by stem/progenitor cells. Hepatology. 
2013 Oct 1. PubMed PMID: 24115180. 
17. Roskams T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X, et al. 
Oxidative Stress and Oval Cell Accumulation in Mice and Humans with Alcoholic and 
Nonalcoholic Fatty Liver Disease. The American journal of pathology. 
2003;163(4):1301-11. 
18. Fotiadu A, Tzioufa V, Vrettou E, Koufogiannis D, Papadimitriou CS, 
Hytiroglou P. Progenitor cell activation in chronic viralhepatitis. Liver international : 
official journal of the International Association for the Study of the Liver. 2004 
Jun;24(3):268-74. PubMed PMID: 15189279. Epub 2004/06/11. eng. 
19. Saxena R, Hytiroglou P, Thung SN, Theise ND. Destruction of canals of 
hering in primary biliary cirrhosis. Human Pathology. 2002;33(10):983-8. 
20. Khan FM, Komarla AR, Mendoza PG, Bodenheimer HC, Jr., Theise ND. 
Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis: "minimal 
change PBC"? Hepatology. 2013 Feb;57(2):700-7. PubMed PMID: 22911653. 
21. Nakanuma Y, Zen Y, Harada K, Sasaki M, Nonomura A, Uehara T, et al. 
Application of a new histological staging and grading system for primary biliary 
cirrhosis to liver biopsy specimens: Interobserver agreement. Pathology international. 
2010 Mar;60(3):167-74. PubMed PMID: 20403042. 
22. Kakuda Y, Harada K, Sawada-Kitamura S, Ikeda H, Sato Y, Sasaki M, et al. 
Evaluation of a new histologic staging and grading system for primary biliary cirrhosis 
in comparison with classical systems. Hum Pathol. 2013 Jun;44(6):1107-17. PubMed 
PMID: 23313306. 
-29- 
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. 
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. 
The American journal of gastroenterology. 1999 Sep;94(9):2467-74. PubMed PMID: 
10484010. Epub 1999/09/14. eng. 
24. Intraobserver and interobserver variations in liver biopsy interpretation in 
patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. 
Hepatology. 1994 Jul;20(1 Pt 1):15-20. PubMed PMID: 8020885. Epub 1994/07/01. 
eng. 
25. Saxena R, Theise N. Canals of Hering: recent insights and current knowledge. 
Seminars in liver disease. 2004 Feb;24(1):43-8. PubMed PMID: 15085485. Epub 
2004/04/16. eng. 
26. Scheuer P. Primary biliary cirrhosis. Proceedings of the Royal Society of 
Medicine. 1967 Dec;60(12):1257-60. PubMed PMID: 6066569. Pubmed Central 
PMCID: PMC1901478. Epub 1967/12/01. eng. 
27. Ding ZY, Jin GN, Liang HF, Wang W, Chen WX, Datta PK, et al. 
Transforming growth factor beta induces expression of connective tissue growth factor 
in hepatic progenitor cells through Smad independent signaling. Cellular signalling. 
2013 Oct;25(10):1981-92. PubMed PMID: 23727026. 
28. Delladetsima J, Alexandrou P, Giaslakiotis K, Psichogiou M, Hatzis G, Sypsa 
V, et al. Hepatic progenitor cells in chronic hepatitis C: a phenomenon of older age and 
advanced liver disease. Virchows Archiv : an international journal of pathology. 2010 
Oct;457(4):457-66. PubMed PMID: 20721577. 
29. Skoien R, Richardson MM, Jonsson JR, Powell EE, Brunt EM, 
Neuschwander-Tetri BA, et al. Heterogeneity of fibrosis patterns in non-alcoholic fatty 
liver disease supports the presence of multiple fibrogenic pathways. Liver international : 
official journal of the International Association for the Study of the Liver. 2013 
Apr;33(4):624-32. PubMed PMID: 23356584. 
30. Svegliati-Baroni G, Ridolfi F, Hannivoort R, Saccomanno S, Homan M, de 
Minicis S, et al. Bile acids induce hepatic stellate cell proliferation via activation of the 
epidermal growth factor receptor. Gastroenterology. 2005;128(4):1042-55. 
31. Harada K, Nakanuma Y. Cholangiopathy with respect to biliary innate 
immunity. International journal of hepatology. 2012;2012:793569. PubMed PMID: 





Preparation of consecutive 
sections from each specimen
CK19 immunostained specimen
Counting CoH in each whole 
specimen





Sirius Red stained specimen
Imaging of specimens at ×20 
magnification
Creation of digital images of 
whole specimens from each 
case on a computer (Fig. 3B)
Quantification of hepatic 
parenchymal area in each 
specimen as pixels
H&E, Reticulin, Azan-Mallory, 
and Orcein stained specimens
Evaluation of staging and 

















































0 1 2 3
CA














































(n = 16) (n = 46)Total bilirubin level after 1 year UDCA treatment
















Over normal range Within normal range














































0 2.5 5 7.5 10 12.5 15
(×10 −
6
)
(×10 −
6
) (×10 −
6
)
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
Fig.5
A B
0
50
100
150
P
B
C
 f
ib
ro
s
is
 0
/1
(n
 =
 4
5
)
C
V
H
 
F
 0
/1
(n
 =
 1
2
)
N
A
F
L
D
 
S
ta
g
e
 0
/1
/2
(n
 =
 7
)
N
o
rm
a
l
(n
 =
 1
1
)
** *
0
50
100
150
N
A
F
L
D
 
S
ta
g
e
 3
/4
(n
 =
 6
)
P
B
C
 f
ib
ro
s
is
 2
/3
(n
 =
 1
7
)
C
V
H
 
F
 2
/3
/4
(n
 =
 2
4
)
*
*
(×10 −
6
) (×10 −
6
)
c
/p
 r
a
ti
o
c
/p
 r
a
ti
o
